Turnstone Biologics Reports Initial Data From Phase 1 Trial Of TIDAL-01 In Metastatic Colorectal Cancer; Overall Response Rate Of 25% And 50% Disease Control Rate Observed In First 4 Evaluable Patients
Portfolio Pulse from Benzinga Newsdesk
Turnstone Biologics Corp. (NASDAQ:TSBX) reported positive initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic colorectal cancer. The trial showed a 25% overall response rate and a 50% disease control rate in the first four evaluable patients. The treatment demonstrated favorable tolerability and manufacturing success.
August 14, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Turnstone Biologics Corp. (NASDAQ:TSBX) reported positive initial data from its Phase 1 trial of TIDAL-01 in metastatic colorectal cancer, showing a 25% overall response rate and a 50% disease control rate in the first four evaluable patients. The treatment also demonstrated favorable tolerability and manufacturing success.
The positive initial data from the Phase 1 trial of TIDAL-01 in metastatic colorectal cancer is likely to boost investor confidence in Turnstone Biologics. The favorable response rates and tolerability profile suggest potential for future success, which could drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100